February 17, 2021
COVID-19 Accelerating RWE Use in Clinical Settings: ConcertAI
NEWS Media Coverage
A leader from the clinical data solutions firm explains how the challenges created by the pandemic have helped fuel creativity and innovation in studies.
Real-world data (RWD) and real-world evidence (RWE) both are increasingly important tools in healthcare and research, but there are important differences. The US Food and Drug Administration (FDA) defines RWD as “the data relating to patient health status,” and RWE as “the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD.”
Jeff Elton, CEO of health data technology specialists ConcertAI, points out that while both real-world data (RWD) and real-world evidence (RWE) are useful in clinical research, the latter goes further.
“Real-world data is just that—it’s the data elements,” Elton explained. “Real-world evidence isn’t just a data element—it goes beyond that. I’ve been able to pull data together and link it to an outcome, or interest that can be part of a regulatory or reimbursement decision. It’s a lot more meaningful.”